This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): NSD-644
Description: NSD-644 is a triple monoamine re-uptake inhibitor, increasing the effect of serotonin, noradrenalin and dopamine. These neurotrasmitters are involved in the regulation of mood, pain and anxiety.
Deal Structure: NSD-644 is the first development candidate in NeuroSearchs alliance agreement with GSK. Under the terms of the option agreement, GSK has accepted NSD-644 as a CEEDD (Center of Excellence for External Drug Discovery) candidate for further development, which means that GSK will pay milestone payments to NeuroSearch up to and including the initiation of Phase I studies. NeuroSearch retains responsibility for the clinical development of NSD-644 until completion of Proof-of-Concept (through Phase IIa), while GSK will be responsible for clinical development hereafter, as well as for production and marketing of the product. GSK will pay milestones to NeuroSearch through to market launch as well as double-digit royalties on global sales of the product.
In December 2003, GlaxoSmithKline and NeuroSearch entered into a five-year research and development alliance. The alliance comprises a number of research programs within ion channels and the treatment of...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc
Additional information available to subscribers only: